Potential Therapeutic Strategies to Interrupt Insulin-Like Growth Factor Signaling in Breast Cancer

Seminars in Oncology

Volumn 30, Issue 5 SUPPL. 16, 2003, Pages 125-132

  Byron, Sara A ^a   Yee, Douglas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DOXORUBICIN; FLUOROURACIL; GROWTH HORMONE; INTERLEUKIN 1BETA; PROTEIN P53; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; WT1 PROTEIN;

ASTROCYTOMA; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; DNA DAMAGE; DOWN REGULATION; EWING SARCOMA; GENE EXPRESSION; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

EID: 0242637268     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.014     Document Type: Conference Paper

References (65)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2:170-175, 2000
3. D'Ercole AJ, Stiles AD, Underwood LE: Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A 81:935-939, 1984
4. Yee D, Paik S, Lebovic GS, et al: Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509-517, 1989
5. Giani C, Cullen KJ, Campani D, et al: IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 41:43-50, 1996
6. Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22:31-38, 1992
7. Porras A, Alvarez AM, Valladares A, et al: p42/p44 mitogen-activated protein kinases activation is required for the insulin-like growth factor-I/insulin induced proliferation, but inhibits differentiation, in rat fetal brown adipocytes. Mol Endocrinol 12:825-834, 1998
8. Ahmad S, Singh N, Glazer RI: Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol 58:425-430, 1999
9. Monno S, Newman MV, Cook M, et al: Insulin-like growth factor I activates c-jun N-terminal kinase in MCF-7 breast cancer cells. Endocrinology 141:544-550, 2000
10. Zhang X, Yee D: Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res 62:4369-4375, 2002
11. Hadsell DL, Murphy KL, Bonnette SG, et al: Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 19:889-898, 2000
12. Yakar S, Green J, LeRoith D: Serum IGF-I levels as a risk marker in mammary tumors. Proc Endocr Soc 201:P1-242, 2001 (abstr)
13. Bruning PF, Van Doorn J, Bonfrer JM, et al: Insulin-like growth-factor-binding protein 3 is decreased in early- stage operable pre-menopausal breast cancer. Int J Cancer 62:266-270, 1995
14. Toniolo P, Bruning PF, Akhmedkhanov A, et al: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828-832, 2000
15. Pollak M, Costantino J, Polychronakos C, et al: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82:1693-1697, 1990
16. Reed MJ, Christodoulides A, Koistinen R, et al: The effect of endocrine therapy with medroxyprogesterone acetate, 4- hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int J Cancer 52:208-212, 1992
17. Baserga R, Sell C, Porcu P, et al: The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif 27:63-71, 1994
18. Cullen KJ, Yee D, Sly WS, et al: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48-53, 1990
19. Milazzo G, Giorgino F, Damante G, et al: Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52:3924-3930, 1992
20. Pezzino V, Papa V, Milazzo G, et al: Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann N Y Acad Sci 784:189-201, 1996
21. Resnik JL, Reichart DB, Huey K, et al: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58:1159-1164, 1998
22. Turner BC, Haffty BG, Narayanan L, et al: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:3079-3083, 1997
23. Berns EM, Klijn JG, van Staveren IL, et al: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036-1039, 1992
24. Rocha RL, Hilsenbeck SG, Jackson JG, et al: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clin Cancer Res 3:103-109, 1997
25. Lee AV, Jackson JG, Gooch JL, et al: Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:787-796, 1999
26. Tanaka S, Wands JR: A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 98:2100-2108, 1996
27. Lee AV, Weng CN, Jackson JG, et al: Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 152:39-47, 1997
28. Burgaud JL, Baserga R: Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor. Exp Cell Res 223:412-419, 1996
29. Lu Y, Zi X, Zhao Y, et al: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857, 2001
30. Ingle JN, Suman VJ, Kardinal CG, et al: A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85:1284-1292, 1999
31. Pradhananga S, Wilkinson I, Ross RJ: Pegvisomant: Structure and function. J Mol Endocrinol 29:11-14, 2002
32. Friend KE: Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res A:S121-123, 2001 (suppl 11)
33. Szepeshazi K, Schally AV, Armatis P, et al: Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 142:4371-4378, 2001
34. Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49:6237-6241, 1989
35. Arteaga CL, Kitten LJ, Coronado EB, et al: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418-1423, 1989
36. Li SL, Liang SJ, Guo N, et al: Single-chain antibodies against human insulin-like growth factor I receptor: Expression, purification, and effect on tumor growth. Cancer Immunol Immunother 49:243-252, 2000
37. Brunner N, Yee D, Kern FG, et al: Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur J Cancer 4:562-569, 1993
38. Benini S, Manara MC, Baldini N, et al: Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 7:1790-1797, 2001
39. Perer ES, Madan AK, Shurin A, et al: Insulin-like growth factor I receptor antagonism augmenrs response to chemoradiation therapy in colon cancer cells. J Surg Res 94: 1-5, 2000
40. Clemmons DR, Cascieri MA, Camacho-Hubner C, et al: Discrete alterations of the insulin- like growth factor I molecule which alter its affinity for insulin-like growth factor-binding proteins result in changes in bioactivity. J Biol Chem 265:12210-12216, 1990
41. Pietrzkowski Z, Wernicke D, Porcu P, et al: Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res 52:6447-6451, 1992
42. Pietrzkowski Z, Mulholland G, Gomella L, et al: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53:1102-1106, 1993
43. Figueroa JA, Sharma J, Jackson JG, et al: Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 157:229-236, 1993
44. Yee D, Jackson JG, Kozelsky TW, et al: Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ 5:73-77, 1994
45. Van den Berg CL, Cox GN, Stroh CA, et al: Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 33:1108-1113, 1997
46. Nickerson T, Huynh H, Pollak M: Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 237:690-693, 1997
47. Oh Y, Muller HL, Lamson G, et al: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971, 1993
48. Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181-12188, 1997
49. Ricort J-M, Binoux M: Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway. J Biol Chem 277:19448-19454, 2002
50. Pares A, Planas R, Torres M, et al: Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 28:615-621, 1998
51. Flora K, Hahn M, Rosen H, et al: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93:139-143, 1998
52. Zi X, Zhang J, Agarwal R, et al: Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60:5617-5620, 2000
53. Chernicky CL, Tan H, Yi L, et al: Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo. Mol Pathol 55:102-109, 2002
54. Neuenschwander S, Roberts CT Jr, LeRoith D: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinol 136:4298-4303, 1995
55. Macaulay VM, Salisbury AJ, Bohula EA, et al: Down-regulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 20: 4029-4040, 2001
56. Andrews DW, Resnicoff M, Flanders AE, et al: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19: 2189-2200, 2001
57. Werner H, Rauscher FJ III, Sukhetme VP, et al: Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem 269:12577-12582, 1994
58. Werner H, Karnieli E, Rauscher FJ III, et al: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. PNAS 93:8318-8323, 1996
59. Carlberg M, Dricu A, Blegen H, et al: Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem 271:17453-17462, 1996
60. Parrizas M, Gazit A, Levitzki A, et al: Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinol 138:1427-1433, 1997
61. Blum G, Gazit A, Levitzki A: Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39:15705-15712, 2000
62. Reiss K, D'Ambrosio C, Tu X, et al: Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res 4:2647-2655, 1998
63. D'Ambrosio C, Ferber A, Resnicoff M, et al: A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 56:4013-4020, 1996
64. Dunn SE, Ehrlich M, Sharp NJ, et al: A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58:3353-3361, 1998
65. Shen WH, Zhou JH, Broussard SR, et al: Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res 62:4746-4756, 2002